Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Vicky Sanchez Perez"'
Autor:
Markus Joerger, Emiliano Calvo, Heinz Läubli, Juanita Lopez, Elena Garralda, Dagmar Hess, Elena Corral de la Fuente, Christoph Bucher, Guzman Alonso, Sangeeta Jethwa, David König, Vicky Sanchez Perez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background ANV419 is a stable antibody–cytokine fusion protein consisting of interleukin-2 (IL-2) fused to an anti-IL-2 monoclonal antibody that sterically hinders binding of IL-2 to the α subunit of its receptor but has selective affinity for the
Externí odkaz:
https://doaj.org/article/c922b1eb4e8b44009c63d9e58c5680a1
Autor:
Christoph Bucher, Guzman Alonso, Juanita Lopez, Emiliano Calvo, Markus Joerger, Vicky Sanchez Perez, Elena Corral, Daniela Di Blasi, Kirsten Richter, Christoph Huber, Julie Mouton, Silvio Costanzo, Sangeeta Jethwa, Elena Gerralda, Heinz Läubli
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9cad13bbf181eddbe773f6aacca7c18
https://doi.org/10.1136/jitc-2022-sitc2022.0631
https://doi.org/10.1136/jitc-2022-sitc2022.0631
Autor:
Elena Garralda, Alonso Guzman, Juanita Lopez, Vicky Sanchez-Perez, Heinz Läubli, Emiliano Calvo, Christoph Huber, Nicole Egli, Aswathy Nair, Julie Mouton, Kirsten Richter, Carlo Lanza, Sangeeta Jethwa, Silvio Costanzo, Christoph Bucher
Publikováno v:
Cancer Research. 82:CT140-CT140
Developing a safe and effective non-alpha IL-2R agonist to enhance the numbers and activation status of immune effector cells for the treatment of cancer has remained an elusive goal since the initial approval of Interleukin-2 (IL-2). ANV419 comprise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15e499f791c3b0efb192f0d72ea4ad17
https://doi.org/10.1158/1538-7445.am2022-ct140
https://doi.org/10.1158/1538-7445.am2022-ct140
Autor:
Heinz Läubli, Guzman Alonso, Juanita Suzanne Lopez, Emiliano Calvo, Vicky Sanchez Perez, Daniela Di Blasi, Aswathy Nair, Kirsten Richter, Christoph Huber, Nicole Egli, Julie Mouton, Silvio Costanzo, Andreas Katopodis, Sangeeta Jethwa Schnetzler, Christoph Marcus Bucher, Elena Garralda
Publikováno v:
Journal of Clinical Oncology. 40:e21552-e21552
e21552 Background: IL-2R agonists that are well tolerated and can selectively enhance immune activation may improve outcomes of patients with cancer. ANV419 is a potent and highly selective IL-2Rβγ binding agonist, consisting of an antibody specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0975560981836a07d9ad4c1aa7c7f73d
https://doi.org/10.1200/jco.2022.40.16_suppl.e21552
https://doi.org/10.1200/jco.2022.40.16_suppl.e21552
Autor:
Anna Rachel Minchom, Vicky Sanchez Perez, Cienne Morton, Thubeena Manickavasagar, George Nintos, Julia Elizabeth Lai-Kwon, Christina Guo, Nina Tunariu, Tom Parker, Toby Prout, Mona Parmar, Alison Joanne Turner, Laura Finneran, Emma Hall, Jonathan A. Pachter, Louis J. Denis, James F. Spicer, Udai Banerji
Publikováno v:
Journal of Clinical Oncology. 40:9018-9018
9018 Background: VS-6766 is a small molecule RAF/MEK clamp that results in the reduction of p-MEK and p-ERK. Preclinical data show synergy of VS-6766 with the mTOR inhibitor everolimus across a panel of KRAS mutated (mt) NSCLC cell lines. This clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cd15485b7698b5ed0f614aa11755ea0
https://doi.org/10.1200/jco.2022.40.16_suppl.9018
https://doi.org/10.1200/jco.2022.40.16_suppl.9018